Terms: = Ovarian cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
574 results:
1. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
2. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
3. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
4. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
5. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
6. LRP8 promotes tumorigenesis in ovarian cancer through inhibiting p53 signaling.
Xu Y; Zhou Y; Yi X; Nie X
Cell Biol Int; 2024 May; 48(5):626-637. PubMed ID: 38263609
[TBL] [Abstract] [Full Text] [Related]
7. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract] [Full Text] [Related]
8. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
9. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H; Chen C; Wang D; Zhu Y; Chen P
BMC Cancer; 2023 Dec; 23(1):1210. PubMed ID: 38066448
[TBL] [Abstract] [Full Text] [Related]
10. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract] [Full Text] [Related]
11. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With ovarian cancer.
Dobilas A; Chen Y; Brueffer C; Leandersson P; Saal LH; Borgfeldt C
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):763-770. PubMed ID: 38035709
[TBL] [Abstract] [Full Text] [Related]
12. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
13. tp53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
[TBL] [Abstract] [Full Text] [Related]
14. Is HOXA5 a Novel Prognostic Biomarker for Uterine Corpus Endometrioid Adenocarcinoma?
Song C; Kim KB; Lee GS; Shin S; Kim B
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834206
[TBL] [Abstract] [Full Text] [Related]
15. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract] [Full Text] [Related]
16. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract] [Full Text] [Related]
17. Establishment and validation of an immune infiltration predictive model for ovarian cancer.
Song Z; Zhang J; Sun Y; Jiang Z; Liu X
BMC Med Genomics; 2023 Sep; 16(1):227. PubMed ID: 37759229
[TBL] [Abstract] [Full Text] [Related]
18. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
19. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
20. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract] [Full Text] [Related]
[Next]
